US Bancorp DE Has $11.09 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

US Bancorp DE lessened its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,019 shares of the company’s stock after selling 2,107 shares during the quarter. US Bancorp DE owned about 0.27% of Axsome Therapeutics worth $11,086,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. WCM Investment Management LLC lifted its stake in Axsome Therapeutics by 0.3% in the third quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock valued at $10,191,000 after buying an additional 347 shares during the period. KBC Group NV lifted its stake in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Axsome Therapeutics by 4.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock valued at $1,780,000 after buying an additional 754 shares during the period. Finally, R Squared Ltd acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $64,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 0.3 %

NASDAQ:AXSM opened at $127.15 on Tuesday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a market cap of $6.20 billion, a PE ratio of -21.23 and a beta of 1.05. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The stock has a 50-day simple moving average of $105.81 and a 200 day simple moving average of $96.81.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on AXSM. HC Wainwright increased their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Mizuho increased their target price on Axsome Therapeutics from $195.00 to $212.00 and gave the company an “outperform” rating in a research note on Wednesday, February 26th. Royal Bank of Canada increased their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Finally, Bank of America increased their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $167.36.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.